The Lymphoma Coalition (LC) continues its quest to improve access to therapy, including clinical trials, in a timely and cost-effective manner for all patients with lymphoma. However, through discussions with LC member countries and findings from the 2016 Lymphoma Global Patient Survey (GPS), LC has identified four impediments that need to be addressed to improve therapy access.
Four impediments that need to be addressed to improve therapy access are:
- Unequal access to clinical trials;
- No or limited funding/reimbursement of therapies, in particular innovative therapies;
- Limited supportive care;
- Limited access to specialists and treatment centres.
The 2017 Report Card on Lymphomas will demonstrate how the impediments in providing timely and cost-effective care have a negative effect on the well-being of patients. The report card will also review, through case studies, what initiatives member countries have undertaken to improve or remove these impediments.